CA-GLOBALITY
Globality, the leader in using artificial intelligence and natural language processing (NLP) to transform the procurement function, today announced it has been named by The AI Journal as the winner of the Best Use of NLP in the 2022 Global Excellence Awards.
This was the biggest year yet for the awards program with more than 250 entries being submitted from across the world. Each entry was reviewed by a 28-person judging panel from across the world with the winner being selected by achieving the highest score. This year the judging panel included representatives from industry dominating brands such as HSBC, Google, Deloitte, Microsoft, and Amazon.
Powered by cutting-edge AI technology, Globality reinvents the procurement process by automating the demand creation, supplier identification, proposal evaluation, and statement of work (SOW) creation process – completely replacing the traditional, outdated Request for Proposal. Its self-service, consumer-like interface uses NLP and machine learning to understand buyers' needs and match companies with suppliers that best meet specific project requirements, all while achieving substantial cost savings and reducing operating expenses.
“We are proud to be recognized by The AI Journal and receive the prestigious Global Excellence Award for Best Use of NLP,” said Lior Delgo, Globality Co-Founder and President. “It reflects the growth and success of Globality’s game-changing AI-powered technology that is helping industry-leading companies such as BT and Santander transform their buying models to manage their company’s spend more efficiently than ever before.
“In today's economic climate especially, sourcing more intelligently and effectively is not just critical to protecting the bottom line, it is key to driving better business outcomes which is exactly what Globality’s technology is empowering our customers to do.”
“Globality has set a high standard for innovation and creativity with its winning entry in the category Best Use of NLP. With this being the biggest year yet, it made the competition for being a finalist tough with innovative, smart, thought-provoking, results-driven entries coming in from companies of all sizes. It is fantastic to see the effort and passion be rewarded by getting the global recognition by winning at the 2022 Global Excellence Awards,” said Tom Allen, Founder and CEO of The AI Journal.
About Globality – Option 1
Globality is the leader in using leading-edge, artificial intelligence-powered technology to dramatically increase cost savings and improve business outcomes that procurement facilitates. Globality’s state-of-the-art digital solution replaces the traditional, outdated Request for Proposal, efficiently and effectively scoping needs, and matches companies with the suppliers that best meet the specific project requirements. By using Globality’s platform, companies achieve substantial cost savings and reduced operating expenses, while also delighting business stakeholders, fostering collaboration, and improving outcomes. For more information, visit www.globality.com
About The AI Journal Global Excellence Awards
The AI Journal’s Global Excellence Awards is a program that recognizes best practices, use cases, campaigns, and exceptional talent from high-performing teams and individuals from companies of all sizes around the world.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221220005034/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Meiji Seika Pharma Partners With MBC BioLabs to Strengthen Global Innovation in Drug Discovery19.12.2025 02:00:00 CET | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Chuo-ku, Tokyo; President & CEO: Toshiaki Nagasato) today announced that it has entered into a partnership agreement with MBC BioLabs which is a private organization supporting the development of biotech startup companies in California’s San Francisco Bay Area. MBC BioLabs provides fully equipped research facilities and a supportive community that help biotech entrepreneurs accelerate from concept to company. By removing the burden of building and maintaining laboratory infrastructure, resident companies can focus early on research and development while efficiently advancing commercialization. Through this partnership, Meiji Seika Pharma will further advance its open-innovation initiatives and strengthen research and development in its priority therapeutic areas: infectious diseases, hematologic diseases, and immune-inflammatory diseases. By engaging with the entrepreneurs and startup community at MBC BioLabs, the company aims to discover inn
Enry's Island SpA Strengthens Its Leadership in Venture Capital with Explosive Growth and Redesigns the Future of VC Through Gaming19.12.2025 00:34:00 CET | Press release
Announcement of Enry’s Island AdVentures: the world’s first video game to learn how to launch and scale startups, focused on democratizing innovation for “Long Tail Users” Enry’s Island SpA (WBAG:EIOS), the world’s first publicly listed venture builder, announces a new era of growth, innovation, and the democratization of Venture Capital (VC). The company has delivered exceptional results, consolidating its position as an industry leader through a strategic positioning in the rapidly expanding gaming market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218742236/en/ Record Growth and Performance Enry’s Island SpA has demonstrated an extraordinary growth trajectory and a strong financial and operational track record: Revenues: +250% year-over-year (YoY). Exit: $3.6M in exits realized via IPO. Portfolio: 1 IPO of a portfolio company completed in December 2024, with an additional 2 IPOs expected in 2026. The performance of
500 Global Expands Africa Presence; Selected to Advance Digital Morocco 2030 Strategy18.12.2025 21:37:00 CET | Press release
Part of the Digital Morocco 2030 strategy, 500 Global has been selected to support the Startup Venture Building (Startup VB) initiative. 500 Global, one of the world’s most active venture capital firms1, announced it has been selected to support the Ministry-led Startup VB initiative, a flagship program under the Digital Morocco 2030 strategy2. This announcement marks a significant milestone in 500 Global’s continued expansion across the African continent and its work collaborating with governments to strengthen national innovation ecosystems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218363323/en/ Announcement of 500 Global's continued expansion across Africa and support of Digital Morocco 2030 Launched by the Ministry of Digital Transition and Administrative Reform (Ministry) and deployed by TAMWILCOM, the Startup VB initiative is a flagship program under the Digital Morocco 2030 strategy. Startup VB aims to streng
Neural Concept Closes $100M Funding Round Led by Growth Equity at Goldman Sachs Alternatives to Scale AI-Native Engineering18.12.2025 17:00:00 CET | Press release
New capital accelerates Neural Concept’s ability to deliver transformative technologies and enterprise-wide AI impact across advanced industrial workflows.Platform delivers CAD-native, physics-aware AI and deep reasoning for engineering, saving customers $50 million annually, reducing late-stage redesigns by 30-50% and accelerating time to market by up to two years.The company has generated a fourfold increase in enterprise revenue over the past 18 months.More than 50 global companies are actively relying on the platform, including General Motors, General Electric Vernova, Leonardo Aerospace, Eaton, Safran, Renault Group and multiple Formula 1 teams. Neural Concept, a global AI platform and leader in Engineering Intelligence powering next-generation product development, today announced it raised a $100 million Series C funding round led by Growth Equity at Goldman Sachs Alternatives, with existing investors Forestay Capital, Alven, HTGF, D.E. Shaw Ventures and Aster Capital. This press
Croma-Pharma Introduces New Medical Device for the Preparation of Autologous PRP | Fluid- PRF18.12.2025 16:57:00 CET | Press release
Croma-Pharma, a global player in minimally invasive aesthetic medicine, proudly announces the launch of its new medical device that is used for the preparation of autologous Platelet-Rich Plasma (PRP) | Fluid-Platelet-Rich Fibrin (Fluid-PRF).1 This launch represents continued progress in Croma’s mission to provide healthcare professionals state-of-the-art tools for their practice. With its innovative design and optimized separation technology, Exprecell™ enables the efficient preparation of autologous blood concentrates, without the use of anticoagulants, resulting in the formation of Fluid-PRF, a biologically active concentrate that retains the regenerative properties of platelets and leukocytes, yet stays liquid for a defined period.1 What makes Exprecell™ special?MDR certification: Exprecell™ is MDR-certified, meeting stringent EU regulatory requirements to ensure the safe, controlled and standardized preparation of autologous Platelet-Rich Plasma (PRP) | Fluid-Platelet-Rich Fibrin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
